整合性分析策略,以指导地幔细胞淋巴瘤的个性化治疗:一个试点研究
Yang Liu1, Holly A Hill1,2, Yijing Li1
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
NPJ precision oncology
|November 21, 2025
概括
膜细胞淋巴瘤 (MCL) 在初始治疗后经常复发. 一个新的多模式平台有助于为复发性或耐药性MCL患者确定向疗法,改善治疗选择.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 膜细胞淋巴瘤 (MCL) 最初对治疗有反应,但容易复发.
- 布鲁顿的氨酸激酶抑制剂 (BTKi) 是有效的,但耐药性最终发展,需要新的治疗策略.
- 由于复杂的抗性机制,难以预测复发性/耐药性MCL后续治疗的反应.
研究的目的:
- 开发和验证一个多模式的分析平台,用于识别复发性/耐药性MCL的向疗法.
- 整合基因表达概况,整个外体序列和药物查,以预测患者的反应.
- 为个人MCL患者确定可操作的治疗候选者.
主要方法:
- 使用定制基因组和基因组变异分析,对20个MCL样本的基因表达概况.
- 在实验室中对22种治疗药物进行对MCL细胞的查.
- 整体外基因组测序以确定与丰富途径相关的流行突变.
- 在患者衍生的异种移植小鼠模型中测试选择的治疗方法.
主要成果:
- 确定了有助于MCL进展和抵抗的失调信号通路.
- 发现了与特定的丰富途径相关的可操作突变.
- 在基于整合性分析的基础上,成功确定了三个单独的MCL患者的顶级治疗候选者.
- 证明了患者衍生的异种移植模型在预测临床反应方面的潜力.
结论:
- 开发的多模式分析平台为BTKi复发/耐药性MCL的个性化治疗选择提供了一个有前途的方法.
- 这种综合性策略针对关键的细胞通路和遗传改变,以克服治疗耐药性.
- 该平台有潜力指导临床决策并改善难以治疗的MCL患者的治疗结果.
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Humanistic Therapy
308
Humanistic therapies emphasize personal growth, self-understanding, and the fulfillment of human potential. Rooted in the belief that individuals inherently strive toward self-actualization, these approaches encourage clients to explore their feelings and experiences in a supportive, nonjudgmental environment. Humanistic therapies differ from psychodynamic approaches by focusing on conscious experiences, present circumstances, and the potential for self-improvement rather than past conflicts...
308
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


